BioNTech’s (BNTX) Buy Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of BioNTech (NASDAQ:BNTX) in a report issued on Wednesday morning,MarketScreener reports.

Several other research firms have also issued reports on BNTX. Raymond James Financial reissued an “outperform” rating on shares of BioNTech in a research report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a report on Wednesday, March 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of BioNTech in a report on Tuesday, March 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $140.00 price objective on shares of BioNTech in a research report on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.73.

BioNTech Price Performance

BNTX opened at $85.68 on Wednesday. The company’s 50 day simple moving average is $103.70 and its 200 day simple moving average is $101.60. The stock has a market capitalization of $20.56 billion, a PE ratio of -16.35 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently made changes to their positions in the stock. Dodge & Cox raised its stake in shares of BioNTech by 315.7% during the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after acquiring an additional 2,769,654 shares during the last quarter. GSK plc bought a new position in shares of BioNTech during the 4th quarter worth approximately $84,711,000. BNP Paribas Financial Markets lifted its stake in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares during the last quarter. Bank of America Corp DE raised its holdings in BioNTech by 344.4% during the 3rd quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock valued at $56,544,000 after acquiring an additional 444,332 shares during the period. Finally, Voloridge Investment Management LLC purchased a new stake in BioNTech during the 4th quarter worth about $41,656,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.